Apremig ODT75 mg

Apremig ODT is a calcitonin gene-related peptide (CGRP) receptor antagonist (gepant class) approved for two distinct uses in adults:

Established / FDA-Approved Uses

• Acute treatment of migraine with or without aura in adults.
• Preventive treatment of episodic migraine in adults, dosed every other day.

Apremig ODT is not indicated for the treatment of cluster headache or other headache disorders, and it is not approved for use in children.

Each orally disintegrating tablet (ODT) contains Rimegepant 75 mg (present as rimegepant sulfate).

Apremig ODT is an orally administered, small-molecule calcitonin gene-related peptide (CGRP) receptor antagonist belonging to the "gepant" class of anti-migraine agents. Unlike triptans, Apremig ODT does not act on serotonin receptors and does not cause vasoconstriction, which distinguishes its use in some patients with cardiovascular risk factors, under medical guidance. Apremig ODT is formulated as an orally disintegrating tablet (ODT) that dissolves on or under the tongue without the need for water.

Apremig ODT belongs to the CGRP (Calcitonin Gene-Related Peptide) Receptor Antagonist class — also known as the "Gepant" class of anti-migraine agents.

Rimegepant is a selective, competitive antagonist of the calcitonin gene-related peptide (CGRP) receptor. CGRP is a neuropeptide released during migraine attacks that causes vasodilation and neurogenic inflammation, contributing to migraine pain. By blocking CGRP receptor activation, Rimegepant interrupts this pathway both acutely (aborting an ongoing attack) and prophylactically (reducing attack frequency when dosed every other day).

Pharmacokinetics

• Absorption: Peak plasma concentration reached in approximately 1.5 hours after administration of the orally disintegrating tablet.
• Metabolism: Primarily via CYP3A4, with a minor contribution from CYP2C9.
• Elimination half-life: Approximately 11 hours.
• Excretion: Mainly via the biliary/fecal route, with a smaller portion excreted renally.

Apremig ODT orally disintegrating tablets (ODT) should be administered as follows:

• Dry hands before handling the tablet.
• Peel back the foil of the blister pack (do not push the tablet through the foil).
• Immediately place the tablet on or under the tongue, where it will disintegrate in saliva; it may be swallowed with or without water.
• Use the tablet immediately after removing it from the blister; do not store it outside the packaging.
• May be taken with or without food.

The most clinically significant interactions with Apremig ODT involve drugs that alter CYP3A4 activity, since Apremig ODT is primarily metabolized by this enzyme.

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir): Significantly increase Apremig ODT plasma concentration; concomitant use should be avoided.
• Moderate CYP3A4 inhibitors: Increase exposure to Apremig ODT; another dose should not be taken within 48 hours of the inhibitor.
• Strong or moderate CYP3A4 inducers (e.g., rifampin, carbamazepine, phenytoin, St. John's Wort): May substantially reduce Apremig ODT concentrations and efficacy; concomitant use should be avoided.
• Potent P-glycoprotein (P-gp) inhibitors: May increase exposure to Apremig ODT; another dose should not be taken within 48 hours.

The most commonly reported adverse effect with Apremig ODT is nausea. Other effects reported include:

• Nausea (most common, seen with both acute and preventive use)
• Abdominal pain and dyspepsia (more common with preventive, every-other-day dosing)
• Hypersensitivity reactions, including dyspnea and rash, in a small proportion of patients (see Precautions and Warnings for details)

Most adverse effects are mild to moderate in severity. Patients should seek prompt medical attention for any signs of a serious allergic reaction.

Pregnancy: Data on the use of Apremig ODT in pregnant women are limited and insufficient to establish a drug-associated risk of major birth defects or miscarriage. Animal reproduction studies showed adverse developmental effects only at exposures associated with maternal toxicity. Apremig ODT should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus, and only under medical supervision.

Lactation: Limited data suggest that Apremig ODT passes into breast milk in small amounts (relative infant dose estimated at less than 1%). The clinical effects on a breastfed infant are not fully established. A physician should be consulted to weigh the benefits of treatment against any potential risk to the infant before using Apremig ODT while breastfeeding.

Hypersensitivity reactions: Serious hypersensitivity reactions, including anaphylaxis, dyspnea, and rash, have been reported with Apremig ODT, in some cases occurring days after administration. Apremig ODT should be discontinued immediately if a hypersensitivity reaction occurs, and should not be re-administered.

New-onset or worsening hypertension: Cases have been reported post-marketing. Blood pressure should be monitored as clinically indicated, and discontinuation of Apremig ODT considered if blood pressure becomes inadequately controlled.

Raynaud's phenomenon: New onset or worsening of pre-existing Raynaud's phenomenon has been reported; discontinue Apremig ODT if symptoms develop or worsen.

Hepatic effects: Rare reports of elevated liver enzymes/hepatotoxicity have been noted with Apremig ODT; use with caution in patients with hepatic impairment, and avoid use in severe (Child-Pugh C) hepatic impairment.

Dosing limits: Do not exceed the maximum labeled dose or frequency of Apremig ODT for either acute or preventive use (see Dosage and Administration).

There is limited clinical experience with overdose of Apremig ODT. No specific antidote is available. In case of a suspected overdose, seek immediate medical attention or contact a poison control center. Management is supportive, consisting of monitoring of vital signs and clinical status. Because Apremig ODT is highly protein-bound, it is unlikely to be significantly removed by hemodialysis.

Store at room temperature (below 30°C), away from light and moisture. Keep the tablet in its original blister pack until immediately before use, and keep out of reach of children.

Renal impairment: No dose adjustment of Apremig ODT is required in patients with mild, moderate, or severe renal impairment. Use in patients with end-stage renal disease is not recommended.

Hepatic impairment: No dose adjustment is required in mild or moderate hepatic impairment. Use of Apremig ODT in severe hepatic impairment is not recommended (see Precautions and Warnings).

Geriatric patients: No clinically meaningful differences in the pharmacokinetics of Apremig ODT have been observed based on age; no dose adjustment is required based on age alone.

Pediatric patients: See Pediatric Uses.

Pregnancy and lactation: See Pregnancy and Lactation.

For acute treatment, Apremig ODT is used as a single as-needed dose per migraine attack, not on a continuous schedule. For preventive treatment, Apremig ODT is intended for longer-term, ongoing use, taken every other day; response should be reassessed periodically by the prescribing physician, typically after several months of use, to confirm continued benefit.

Rimegepant is classified under: Gepants; CGRP (Calcitonin Gene-Related Peptide) Receptor Antagonists; Anti-migraine agents.

Rimegepant works by selectively and competitively blocking the calcitonin gene-related peptide (CGRP) receptor. CGRP is released from trigeminal sensory nerves during a migraine attack and promotes vasodilation, sensitization of pain pathways, and neurogenic inflammation. By preventing CGRP from binding to its receptor, Rimegepant interrupts the transmission and amplification of migraine pain signals, providing relief during an acute attack and reducing the frequency of attacks when used preventively.

The safety and effectiveness of Apremig ODT have not been established in pediatric patients. Apremig ODT is approved for use in adults only and should not be administered to children or adolescents outside of a clinical trial setting.